We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Instem Plc | LSE:INS | London | Ordinary Share | GB00B3TQCK30 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 830.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMINS
RNS Number : 2507L
Instem plc
17 July 2017
Instem plc
("Instem" or the "Company")
Issue of Equity, Total Voting Rights and PDMR Dealing
Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that, following the exercise of vested EMI share options by an employee, 1,500 ordinary shares of 10p each in the Company ("Ordinary Shares") have been issued.
Application will be made to the London Stock Exchange for the admission of the 1,500 new Ordinary Shares to trading on AIM. Admission is expected to take place at 8.00am on 19 July 2017.
Total Voting Rights
Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 15,866,660 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 15,866,660.
The figure of 15,866,660 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
PDMR Dealing
The Company was notified on 13 July that on 12 July 2017, the DG 2008 Discretionary Settlement (of which David Gare (the Company chairman) and his wife are the trustees) transferred 10,000 Ordinary Shares to David's son Adrian Gare and a further 10,000 to his daughter, Debbie Walker, for nil consideration. Following the transaction, the DG 2008 Discretionary Settlement now has a total interest in 1,398,427 Ordinary Shares, representing approximately 8.81% of the Company's issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities / person closely associated ---- ---------------------------------------------------------------- a) Name David Gare (via the DG 2008 Discretionary Settlement) ---- ------------------------- ------------------------------------- 2 Reason for the notification ---- ---------------------------------------------------------------- a) Position/status Chairman of the Company ---- ------------------------- ------------------------------------- b) Initial notification Initial /Amendment ---- ------------------------- ------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---- ---------------------------------------------------------------- a) Name Instem plc ---- ------------------------- ------------------------------------- b) LEI 213800PILYUFNNROQX68 ---- ------------------------- ------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---- ---------------------------------------------------------------- a) Description Ordinary shares of 10p of the financial each instrument, type of instrument ---- Identification GB00B3TQCK30 code b) Nature of the Transfer of ordinary transaction shares ---- ------------------------- ------------------------------------- c) Price(s) and volume(s) ---- --------------- ----------------- Price(s) Volume(s) ---- --------------- ----------------- 0p 10,000 --------------- ----------------- d) Aggregated information ---- - Aggregated N/A volume - Price e) Date of the 12 July 2017 transaction ---- ------------------------- ------------------------------------- f) Place of the London Stock Exchange transaction (XLON) ---- ------------------------- ------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---- ---------------------------------------------------------------- a) Description Ordinary shares of 10p of the financial each instrument, type of instrument ---- Identification GB00B3TQCK30 code b) Nature of the Transfer of ordinary transaction shares ---- ------------------------- ------------------------------------- c) Price(s) and volume(s) ---- --------------- ----------------- Price(s) Volume(s) ---- --------------- ----------------- 0p 10,000 --------------- ----------------- d) Aggregated information ---- - Aggregated N/A volume - Price e) Date of the 12 July 2017 transaction ---- ------------------------- ------------------------------------- f) Place of the London Stock Exchange transaction (XLON) ---- ------------------------- -------------------------------------
For further information, please contact:
Instem plc +44 (0) 1785 825 600 Phil Reason, CEO Nigel Goldsmith, CFO N+1 Singer (Nominated Adviser & Broker) +44 (0) 20 7496 3000 Richard Lindley James White Walbrook Financial PR +44 (0) 20 7933 8780 Paul Cornelius instem@walbrookpr.com Helen Cresswell Sam Allen Paul Whittington
About Instem
Instem is a leading supplier of IT applications and services to the early development healthcare market delivering compelling solutions for data collection, analysis and regulatory submissions management. Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.
To learn more about Instem solutions and its mission, please visit www.instem.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEBGGDRLDBBGRR
(END) Dow Jones Newswires
July 17, 2017 06:27 ET (10:27 GMT)
1 Year Instem Chart |
1 Month Instem Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions